Eplerenon Accord (Eplerenone)

What Is Eplerenon Accord and What Is It Used For?

Eplerenon Accord is a selective aldosterone antagonist (mineralocorticoid receptor antagonist, or MRA) containing the active substance eplerenone. It is used to treat heart failure by blocking the harmful effects of aldosterone – a hormone that, when elevated, promotes cardiac fibrosis, inflammation, and fluid retention that worsen heart failure.

Eplerenone belongs to a group of medicines called selective aldosterone receptor antagonists. Aldosterone is a hormone produced by the adrenal glands that plays a crucial role in regulating blood pressure, fluid balance, and electrolyte levels. In healthy individuals, aldosterone helps maintain normal sodium and potassium balance. However, in heart failure, aldosterone levels are often abnormally elevated, leading to a cascade of harmful effects on the cardiovascular system.

When aldosterone levels remain chronically high, the hormone promotes myocardial fibrosis (scarring of heart tissue), vascular inflammation, endothelial dysfunction, and excessive sodium and water retention. These pathological changes contribute to progressive cardiac remodeling – the gradual deterioration of heart structure and function that characterizes worsening heart failure. By selectively blocking the mineralocorticoid receptor, eplerenone interrupts these harmful processes and helps preserve cardiac function.

Eplerenon Accord is prescribed in two main clinical scenarios. First, it is used in patients who have recently suffered a myocardial infarction (heart attack) complicated by signs of heart failure or reduced left ventricular function. In this setting, eplerenone has been shown to significantly reduce mortality and morbidity when added to standard post-MI therapy including beta-blockers and ACE inhibitors. Second, it is used in patients with chronic heart failure with persistently mild symptoms (New York Heart Association [NYHA] functional class II) despite optimal treatment with other heart failure medications.

Eplerenone is always used as add-on therapy alongside other guideline-recommended heart failure treatments, including ACE inhibitors (or angiotensin receptor blockers), beta-blockers, and in many cases diuretics. The European Society of Cardiology (ESC) 2023 guidelines and the American Heart Association (AHA)/American College of Cardiology (ACC) 2022 guidelines both recommend mineralocorticoid receptor antagonists as a cornerstone of heart failure therapy with reduced ejection fraction (HFrEF).

Known Brand Names

Eplerenone is available under several brand names internationally, including Eplerenon Accord, Eplerenon Krka, Eplerenone Sandoz, Eplerenon Medical Valley, Eplerenon Bluefish, and Eplerenone Teva. The originator brand is Inspra (Pfizer). All contain the same active ingredient and are bioequivalent, meaning they work identically in the body.

What Should You Know Before Taking Eplerenon Accord?

Before starting eplerenone, your doctor must check your kidney function and potassium levels. The medication is contraindicated in patients with high potassium, severe kidney or liver disease, or those taking strong CYP3A4 inhibitors. Never combine eplerenone with both an ACE inhibitor and an ARB simultaneously.

Eplerenone is a powerful medication that requires careful medical assessment before initiation. Because it affects potassium handling by the kidneys, certain conditions and medication combinations create unacceptable risks. Understanding these contraindications and precautions is essential for safe use. Your prescribing physician will evaluate your individual risk profile before starting treatment.

Contraindications

You must not take Eplerenon Accord if any of the following apply:

• Hyperkalemia: You have elevated potassium levels in your blood (serum potassium > 5.0 mmol/L at initiation)
• Severe renal impairment: Estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m²
• Severe hepatic impairment: Child-Pugh class C liver disease
• Potassium-sparing diuretics: Concurrent use of spironolactone, amiloride, triamterene, or other potassium-sparing agents
• Strong CYP3A4 inhibitors: Ketoconazole, itraconazole, nelfinavir, ritonavir, clarithromycin, telithromycin, or nefazodone – these drugs dramatically increase eplerenone blood levels
• Dual RAAS blockade: Concurrent use of both an ACE inhibitor and an angiotensin receptor blocker (ARB) together with eplerenone
• Allergy: Known hypersensitivity to eplerenone or any of the excipients

Warnings and Precautions

Talk to your doctor before taking Eplerenon Accord if you have any of the following conditions, as they may require dose adjustment, more frequent monitoring, or additional precautions:

• Mild to moderate kidney disease: Reduced renal function increases the risk of hyperkalemia. Patients with mild impairment should start at 25 mg daily; those with moderate impairment may start at 25 mg every other day. Potassium and creatinine must be monitored more frequently.
• Mild to moderate liver disease: While dose adjustment is not required for mild to moderate hepatic impairment, more frequent potassium monitoring is recommended.
• Diabetes mellitus: Patients with diabetes have an inherently higher risk of hyperkalemia, particularly those with diabetic nephropathy. Extra vigilance with potassium monitoring is essential.
• Lithium use: Eplerenone may alter lithium levels when combined with diuretics and ACE inhibitors, potentially leading to lithium toxicity.
• Tacrolimus or ciclosporin use: These immunosuppressants can impair kidney function and increase hyperkalemia risk when combined with eplerenone.

Pregnancy and Breastfeeding

The effects of eplerenone during human pregnancy have not been adequately studied. Animal studies have not shown direct harmful effects on fetal development, but as with all medications, eplerenone should only be used during pregnancy if the potential benefit clearly outweighs the potential risk. Your doctor will carefully weigh the necessity of continued treatment if you become pregnant.

It is not known whether eplerenone passes into human breast milk. Because many drugs are excreted in breast milk and because of the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the medicine to the mother. Discuss this thoroughly with your healthcare provider.

Driving and Operating Machinery

Eplerenone may cause dizziness in some patients. If you experience dizziness after taking the medication, you should not drive or operate heavy machinery until you know how the drug affects you. This risk is particularly relevant during the initial dose titration period and after dose increases.

Excipients

Eplerenon Accord film-coated tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. The tablets also contain less than 1 mmol (23 mg) sodium per tablet, making them essentially sodium-free.

How Does Eplerenon Accord Interact with Other Drugs?

Eplerenone has significant interactions with drugs that raise potassium levels, strong CYP3A4 inhibitors, and certain cardiac medications. The most dangerous interactions involve potassium-sparing diuretics and dual RAAS blockade (ACE inhibitor + ARB), which are contraindicated. Several antifungals, antivirals, and antibiotics can dramatically increase eplerenone blood levels.

Drug interactions with eplerenone fall into two main categories: pharmacokinetic interactions (drugs that affect how eplerenone is metabolized) and pharmacodynamic interactions (drugs that amplify eplerenone's effects on potassium or blood pressure). Eplerenone is primarily metabolized by the cytochrome P450 enzyme CYP3A4, making it susceptible to interactions with CYP3A4 inhibitors and inducers. Additionally, its potassium-sparing mechanism means any drug that also raises potassium can create a dangerous additive effect.

Major Interactions (Contraindicated or Avoid)

Moderate Interactions (Use with Caution)

CYP3A4 Inducers

Drugs that induce CYP3A4 – such as St. John’s wort (hypericum), rifampicin, carbamazepine, phenytoin, and phenobarbital – can significantly increase the metabolism of eplerenone, reducing its blood levels and potentially diminishing its therapeutic effect. If concurrent use is unavoidable, your doctor may need to adjust the eplerenone dose or consider alternative treatments.

Glucocorticoids

Systemic glucocorticoids such as hydrocortisone, prednisone, and prednisolone, as well as tetracosactide (cosyntropin), may reduce the blood pressure-lowering effect of eplerenone through sodium and water retention. This interaction may require dose adjustment of either medication.

Food Interactions

Eplerenon Accord can be taken with or without food. Grapefruit juice is a moderate CYP3A4 inhibitor, but studies have shown it does not significantly affect eplerenone levels at typical dietary intake. However, excessive grapefruit consumption should be avoided. There are no other significant food interactions.

What Is the Correct Dosage of Eplerenon Accord?

The usual starting dose is 25 mg once daily, increased to a target dose of 50 mg once daily after approximately 4 weeks. The maximum daily dose is 50 mg. Dose adjustments are required based on serum potassium levels and kidney function. Eplerenone is taken orally, with or without food.

Eplerenone is normally prescribed as part of a combination regimen for heart failure that typically includes a beta-blocker, an ACE inhibitor (or ARB), and often a loop diuretic. The dosing strategy follows a “start low, go slow” approach to minimize the risk of hyperkalemia and hypotension. Your doctor will individualize your dose based on your clinical response, potassium levels, kidney function, and tolerance of the medication.

Adults

Potassium Monitoring Schedule

Serum potassium and renal function should be measured at the following time points:

• Before initiation – must be < 5.0 mmol/L to start
• Within the first week of treatment
• At one month after starting or any dose change
• Every 3 months during stable maintenance therapy
• After any change in concomitant medications that may affect potassium

Renal Impairment

Children and Adolescents

The safety and efficacy of eplerenone in children and adolescents under 18 years of age have not been established. Eplerenon Accord is not recommended for use in pediatric patients. The landmark clinical trials (EPHESUS and EMPHASIS-HF) enrolled only adult patients, and there is insufficient evidence to support pediatric dosing recommendations.

Elderly Patients

No starting dose adjustment is required for elderly patients based on age alone. However, elderly patients more frequently have reduced kidney function, which may necessitate dose reduction. Age-related decline in renal function should be carefully assessed, and potassium monitoring may need to be more frequent in older patients.

Missed Dose

If you forget to take a dose of Eplerenon Accord:

• If it is more than 12 hours until your next scheduled dose, take the missed dose as soon as you remember
• If it is less than 12 hours until your next dose, skip the missed dose and take the next one at the usual time
• Never take a double dose to compensate for a forgotten tablet

Overdose

If you or someone else takes too much Eplerenon Accord, seek immediate medical attention by contacting your local poison control center or emergency services. No specific antidote for eplerenone exists. The most likely symptoms of overdose are:

• Hypotension (low blood pressure) – manifesting as lightheadedness, dizziness, blurred vision, weakness, or fainting
• Hyperkalemia (high potassium) – manifesting as muscle cramps, diarrhea, nausea, dizziness, or headache

Treatment is supportive and symptomatic. Eplerenone is not significantly removed by hemodialysis. In cases of severe hyperkalemia, standard measures including calcium gluconate, insulin with glucose, and sodium polystyrene sulfonate may be employed.

What Are the Side Effects of Eplerenon Accord?

Like all medicines, eplerenone can cause side effects, although not everyone experiences them. The most clinically significant side effect is hyperkalemia (high potassium). Common side effects include dizziness, diarrhea, nausea, and impaired kidney function. Seek immediate medical attention if you experience facial swelling, difficulty swallowing, or breathing difficulties, as these may indicate a rare allergic reaction.

Side effects are classified by frequency based on data from clinical trials and post-marketing surveillance. Understanding the likelihood and nature of potential side effects helps you make informed decisions about your treatment and know when to seek medical attention. Most side effects are mild to moderate and resolve with dose adjustment or continued treatment.

Hyperkalemia in Clinical Trials

In the EPHESUS trial, serious hyperkalemia (potassium ≥ 6.0 mmol/L) occurred in 5.5% of patients receiving eplerenone compared to 3.9% with placebo. In the EMPHASIS-HF trial, the incidence was 11.8% for potassium > 5.5 mmol/L vs. 7.2% with placebo. Risk factors for hyperkalemia include renal impairment, diabetes, older age, and concomitant use of ACE inhibitors, ARBs, or NSAIDs. Adherence to the recommended potassium monitoring schedule significantly reduces this risk.

Reporting Side Effects

If you experience any side effects, including those not listed here, you can report them to your national pharmacovigilance authority. Reporting helps regulatory agencies continuously monitor the benefit-risk balance of medicines. In the EU, side effects can be reported through national reporting systems. In the US, reports can be submitted to the FDA MedWatch program. In the UK, the Yellow Card Scheme is used for reporting.

How Should You Store Eplerenon Accord?

Store Eplerenon Accord at room temperature with no special storage conditions required. Keep out of sight and reach of children. Do not use after the expiry date printed on the packaging.

Eplerenon Accord film-coated tablets do not require any special storage conditions. Store them in the original packaging to protect from moisture. Keep the medicine out of the sight and reach of children at all times. Do not use this medicine after the expiry date stated on the carton and blister pack. The expiry date refers to the last day of that month.

Do not dispose of medicines via wastewater or household waste. Return unused medicines to your local pharmacy for safe disposal. These measures help protect the environment and prevent accidental exposure.

What Does Eplerenon Accord Contain?

Each Eplerenon Accord tablet contains either 25 mg or 50 mg of the active substance eplerenone. Inactive ingredients include lactose monohydrate, microcrystalline cellulose, hypromellose, croscarmellose sodium, talc, and magnesium stearate.

Active Substance

The active ingredient is eplerenone. Each film-coated tablet contains either 25 mg or 50 mg of eplerenone.

Inactive Ingredients (Excipients)

Tablet core: Lactose monohydrate, microcrystalline cellulose, hypromellose, croscarmellose sodium, talc, magnesium stearate.

Film coating (Opadry 13B52001 yellow): Hypromellose, titanium dioxide (E171), macrogol 400, polysorbate 80, yellow iron oxide (E172), red iron oxide (E172).

Appearance and Pack Sizes

25 mg tablets: Yellow, diamond-shaped, biconvex film-coated tablets, debossed with “E1” on one side. Approximate dimensions: 7.2 mm length × 6.4 mm width × 3.15 mm thickness.

50 mg tablets: Yellow, diamond-shaped, biconvex film-coated tablets, debossed with “E2” on one side. Approximate dimensions: 9.0 mm length × 8.1 mm width × 4.25 mm thickness.

Available in blister packs of 10, 20, 28, 30, 50, 90, or 100 tablets, and perforated unit-dose blisters of 10×1, 20×1, 28×1, 30×1, 50×1, 90×1, or 100×1 tablets. Not all pack sizes may be marketed in all countries.

Marketing Authorization Holder

Accord Healthcare B.V., Winthontlaan 200, 3526 KV Utrecht, The Netherlands.

What Clinical Evidence Supports Eplerenone Use?

Eplerenone’s efficacy in heart failure is supported by two landmark randomized controlled trials: EPHESUS (post-MI heart failure) and EMPHASIS-HF (chronic mild heart failure). Both demonstrated significant reductions in mortality and cardiovascular hospitalizations, forming the evidence base for international guideline recommendations.

The EPHESUS Trial (2003)

The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) was a landmark double-blind, placebo-controlled trial enrolling 6,632 patients who had suffered an acute myocardial infarction complicated by left ventricular dysfunction (ejection fraction ≤ 40%) and clinical signs of heart failure. Patients received eplerenone (up to 50 mg/day) or placebo in addition to optimal medical therapy.

Key findings included a 15% relative risk reduction in all-cause mortality (p = 0.008), a 13% reduction in cardiovascular mortality, and a 15% reduction in the combined endpoint of cardiovascular death or hospitalization. The benefit was observed early, with separation of survival curves within the first 30 days. These results established eplerenone as an important addition to post-MI heart failure therapy.

The EMPHASIS-HF Trial (2011)

The Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) enrolled 2,737 patients with chronic heart failure with reduced ejection fraction (EF ≤ 30% or ≤ 35% with QRS > 130 ms) and NYHA class II symptoms. The trial was stopped early due to overwhelming efficacy.

Eplerenone produced a 37% relative risk reduction in the primary composite endpoint of cardiovascular death or heart failure hospitalization (p < 0.001). All-cause mortality was reduced by 24%, and heart failure hospitalization was reduced by 42%. These results extended the indication for eplerenone beyond post-MI patients to include those with chronic mild heart failure symptoms.

Guideline Recommendations

Based on this evidence, mineralocorticoid receptor antagonists (including eplerenone) are recommended with a Class I, Level of Evidence A recommendation in both the ESC 2023 Heart Failure Guidelines and the AHA/ACC 2022 Heart Failure Guidelines for patients with HFrEF (heart failure with reduced ejection fraction). They are considered one of the four pillars of HFrEF therapy, alongside ACE inhibitors/ARBs/ARNI, beta-blockers, and SGLT2 inhibitors.

Frequently Asked Questions